<?xml version='1.0' encoding='utf-8'?>
<document id="29487084"><sentence text="Biomarkers for In Vivo Assessment of Transporter Function." /><sentence text="Drug-drug interactions are a major concern not only during clinical practice, but also in drug development" /><sentence text=" Due to limitations of in vitro-in vivo predictions of transporter-mediated drug-drug interactions, multiple clinical Phase I drug-drug interaction studies may become necessary for a new molecular entity to assess potential drug interaction liabilities" /><sentence text=" This is a resource-intensive process and exposes study participants, who frequently are healthy volunteers without benefit from study treatment, to the potential risks of a new drug in development" /><sentence text=" Therefore, there is currently a major interest in new approaches for better prediction of transporter-mediated drug-drug interactions" /><sentence text=" In particular, researchers in the field attempt to identify endogenous compounds as biomarkers for transporter function, such as hexadecanedioate, tetradecanedioate, coproporphyrins I and III, or glycochenodeoxycholate sulfate for hepatic uptake via organic anion transporting polypeptide 1B or N1-methylnicotinamide for multidrug and toxin extrusion protein-mediated renal secretion"><entity charOffset="130-146" id="DDI-PubMed.29487084.s6.e0" text="hexadecanedioate" /><entity charOffset="148-165" id="DDI-PubMed.29487084.s6.e1" text="tetradecanedioate" /><entity charOffset="167-182" id="DDI-PubMed.29487084.s6.e2" text="coproporphyrins" /><entity charOffset="197-227" id="DDI-PubMed.29487084.s6.e3" text="glycochenodeoxycholate sulfate" /><entity charOffset="296-317" id="DDI-PubMed.29487084.s6.e4" text="N1-methylnicotinamide" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e0" e2="DDI-PubMed.29487084.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e0" e2="DDI-PubMed.29487084.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e0" e2="DDI-PubMed.29487084.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e0" e2="DDI-PubMed.29487084.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e0" e2="DDI-PubMed.29487084.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e1" e2="DDI-PubMed.29487084.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e1" e2="DDI-PubMed.29487084.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e1" e2="DDI-PubMed.29487084.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e1" e2="DDI-PubMed.29487084.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e2" e2="DDI-PubMed.29487084.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e2" e2="DDI-PubMed.29487084.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e2" e2="DDI-PubMed.29487084.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e3" e2="DDI-PubMed.29487084.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29487084.s6.e3" e2="DDI-PubMed.29487084.s6.e4" /></sentence><sentence text=" We summarize in this review the currently proposed biomarkers and potential limitations of the substances identified to date" /><sentence text=" Moreover, we suggest criteria based on current experiences, which may be used to assess the suitability of a biomarker for transporter function" /><sentence text=" Finally, further alternatives and supplemental approaches to classic drug-drug interaction studies are discussed" /><sentence text="" /></document>